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Mutations in the vasopressin V2 receptor gene are responsible for two human tubular disorders: X-linked congenital nephrogenic
diabetesinsipidus,duetoalossoffunctionofthemutantV2receptor,andthenephrogenicsyndromeofinappropriateantidiuresis,
due to a constitutive activation of the mutant V2 receptor. This latter recently described disease may be diagnosed from infancy
to adulthood, as some carriers remain asymptomatic for many years. Symptomatic children, however, typically present with
clinical and biological features suggesting inappropriate antidiuretic hormone secretion with severe hyponatremia and high urine
osmolality, but a low plasma arginine vasopressin level. To date, only two missense mutations in the vasopressin V2 receptor
gene have been found in the reported patients. The pathophysiology of the disease requires fuller elucidation as the phenotypic
variability observed in patients bearing the same mutations remains unexplained. The treatment is mainly preventive with ﬂuid
restriction, but urea may also be proposed.
1.Introduction
Since 1992, when the vasopressin V2 receptor gene (AVPR2)
sequence that codes for the V2 receptor (V2R) was ﬁrst
described [1], more than 200 mutations in the AVPR2 have
been found in patients presenting with X-linked congenital
nephrogenic diabetes insipidus (cNDI) [2, 3]. Functional
studies of these mutant receptors have demonstrated a
loss of function in the mutated protein that results in the
insensitivity of the renal collecting duct to the action of the
arginine vasopressin hormone (AVP). This in turn leads to
a defect in water reabsorption with polyuria, polydipsia, and
hypernatremic dehydration.
Recently, it was demonstrated that the V2R may be
aﬀected by gain of function mutations that cause a new
syndrome: the nephrogenic syndrome of inappropriate
antidiuresis (NSIAD) [4]. This phenomenon has been ob-
served for other G-protein-coupled receptors, for example,
TSH (thyrotoxicosis), LH (familial male-limited precocious
puberty), PTH-rp (Bloom syndrome), and the calcium
sensing receptors (hypercalciuric hypocalcemia). NSIAD
was subsequently described in two infant boys presenting
with seizures due to severe hyponatremia and high urinary
osmolality, but low plasma AVP levels. AVPR2 sequencing
demonstrated that these two children harbored the arginine-
137-cysteine (R137C) and arginine-137-leucine (R137L)
mutations in their respective V2 receptors. Since 2005,
when the disease was ﬁrst described, all the NSAID patients
presented in the literature have had one of these two AVPR2
mutations [4–10]. Functional studies have shown that both
mutations are responsible for a constitutive activation of the
mutant V2R, leading to inadequate water reabsorption in
spite of low AVP levels [4, 11]. Nevertheless, the clinical
presentations of these NSIAD patients have been highly
variable, with one of them showing severe neurological
consequences, while others were fully asymptomatic with
only a urine dilution defect revealed during water-load
testing [5, 6]. Thus, patients may be diagnosed early in
life or in adulthood, or they may remain asymptomatic.
The diagnosis of NSIAD thus should be systematically
considered in cases of childhood hyponatremia, especially
when associated with high urine osmolality.2 International Journal of Pediatrics
2.Pathophysiology ofNSIAD
AVP is synthesized in the supraoptic and paraventricular
nuclei and acts through three types of AVP receptors: the
V1a receptor (vasopressive eﬀects of AVP), the V1b receptor
found in the adenohypophysis (ACTH secretion), and the
V2 receptor (V2R) localized in the distal renal collecting
duct [12]. At the cellular level, AVP-V2R binding initiates
a cascade of events, with adenosine 3:5-cyclic phosphate
(cAMP) production through stimulated V2R coupling with
the Gαs protein and the activation of adenylyl cyclase. Intra-
cytoplasmic protein phosphorylation by cAMP-dependent
protein kinase A therefore occurs, which leads to the exocytic
insertion of aquaporin 2 (AQP2), a speciﬁc water channel,
into the luminal membrane of the principal cells of the renal
collecting duct, thereby increasing its water permeability.
Under normal conditions, AVP activation of the V2R
also leads to phosphorylation of serine residues located in
the C-terminal receptor tail with, secondarily, β-arrestin
recruitment and V2R internalization [13]. This negative
regulation of the V2R after stimulation by AVP prevents
prolonged and excessive tubular reabsorption of water. In
NSIAD, the constitutively active mutant V2R appears to lose
this important property, at least partly, but by a mechanism
that remains not fully understood.
Functional studies of the R137C- and R137L-V2R
mutants have shown that both mutants have increased basal
cAMP production compared with the Wt-V2R, conﬁrming
their constitutive activity [4, 11]. It has also been shown
that their relatively low amplitude constitutive activities are
only weakly sensitive to the action of a V2R-inverse agonist
like the SR121463 compound [11]. These data suggest that
these mutant receptors are mainly in an almost blocked
conformation and are consistent with Decaux’s observation
that NSIAD patients are insensitive to nonpeptide V2R
inverse agonists [6]. Nevertheless, it has also been shown
that the relatively low AVP-induced stimulation of both
mutants is completely inhibited by V2R inverse agonists.
Therefore, this latter ﬁnding suggests that, although these
mutant receptors are more often in a blocked conformation,
they can also adopt a more ﬂexible conformation capable of
a desensitization/internalization process [11].
3. ClinicalPresentation
All patients diagnosed with NSIAD to date have been boys
and most diagnoses were made during the ﬁrst two years
of life. Most patients appeared to have a relatively clear
phenotype with biological features initially suggesting a
syndrome of inappropriate antidiuretic hormone secretion
(SIADH) with hyponatremia, low serum osmolality, and
unexpectedly high urine osmolality, but low plasma AVP
levels. The main clinical features, seizure or irritability,
appeared to be linked to the severe hyponatremia.
During the neonatal period, boys bearing the mutated
receptor seem able to enough dilute their urine and there-
fore avoid the risk of severe hyponatremia. Indeed, unless
peculiar clinical conditions such as neonatal asphyxia, the
physiological limitation in concentration capacity during the
ﬁrst weeks of life may protect them from excessive water
reabsorption during this period.
Two large kindreds of patients with NSIAD have also
been reported. Decaux et al. reported the ﬁrst kindred and
showed that the male patients in this family had been
diagnosed in adulthood and were doing well, suggesting
thatNSIADconditionsmaysometimesremainunrecognized
until advanced age [6]. The late diagnosis in such patients
may also be explained by the drop in water excretion
naturally observed in the elderly [14].
The female carriers of this X-linked disorder were also
clinically asymptomatic, but some of them demonstrated
an impaired ability to dilute urine during a water-load test
performed with 20mL/kg of water.
More recently, we reported another four-generation
family with NSIAD bearing the R137C-V2R mutation [5]. In
thisfamily,theclinicalpresentationwashighlyvariableinthe
male carriers. Indeed, one of the children had two episodes
of seizures related to hyponatremia with low plasma AVP
level, when he was 10 months and 34 months. Both episodes
occurred during the summertime when large amounts of
water were given to this young boy to prevent dehydration.
His older brother, also bearing the mutated V2R, lived in
the same city and, as far as we know, had the same diet but
remained fully asymptomatic. Unfortunately, a ﬁrst cousin,
also having the same AVPR2 mutation, experienced several
seizure episodes due to recurrent hyponatremia between
27 months and 5 years of age and eventually developed
permanent mental retardation.
A water-load test was performed in the asymptomatic
male carrier (10mL/kg water load) and the heterozygous
females(20mL/kgwaterload).Theresultsshowedthatwater
loading in the hemizygous male carrier was characterized by
persistent AQP2 urine excretion independently of concomi-
tant vasopressin excretion. This ﬁnding is consistent with
a constitutive activation of the V2R. Slow and incomplete
water elimination with slight hyponatremia was also found.
The female carriers displayed variable biological ﬁndings
after water loading that can be explained by random X
inactivation [5].
Among all the family members explored, only the symp-
tomatic hemizygous male exhibited all the expected signs
under basal conditions: persistent AQP2 urine excretion, low
output of highly concentrated urine, and low plasma and
urine AVP levels. His asymptomatic brother, bearing the
same mutation, had low AQP2 excretion and normal urine
output under basal conditions but displayed a total absence
of downregulation of AQP2 excretion after a cautious
10mL/kg water load.
Concerning the plasma AVP levels measured in these
NSIAD patients, most levels appeared to be low or unde-
tectable in spite of hyponatremia and high urine osmolality.
Nevertheless, in at least one case, it was shown that AVP pro-
duction can persist despite low plasma sodium and plasma
osmolality[8].Thus,ofthefourSIADHcategoriesdescribed,
NSIAD most often belongs to the D group with a low plasma
AVP levels, although it can also be grouped in category B,
which is characterized by a measurable plasma AVP level
[8, 15]. The explanation for this persistent AVP secretionInternational Journal of Pediatrics 3
found in some patients despite low plasma osmolality is
not clear. Nevertheless, this residual and relatively low AVP
secretionshouldhaveonlyaweakactionontheV2Rmutants
given their low aﬃnity for AVP and, mainly, the reduced
cAMP production level observed after stimulation by AVP.
[11].
4. Diagnosisof NSIAD Patients
When NSIAD is suspected, the plasma sodium level, plasma
and urine osmolalities, and plasma AVP level should all be
measuredatthesametimeduringthehyponatremicepisode.
The association of hyponatremia with relatively high urine
osmolality and a low or undetectable plasma AVP level is an
indication for sequencing the AVPR2. In siblings, a water-
load test can be performed in an asymptomatic boy but
cautiously: for example, with only 10mL/kg of water [5]. In
girls, a 20mL/kg water-load test can help to determine their
ability to dilute their urine, as this is variable in heterozygous
females due to random X inactivation and will help in
providing them with recommendations for water intake.
Assessment of the concentration of the plasma von
Willebrand factor (vWF) antigen, which is known to be
increased by AVP stimulation of the so-called “extrarenal
V2R,” does not seem to be helpful in diagnosing NSIAD
patients [4].
5. Management of Patients with NSIAD
In symptomatic NSIAD patients with hyponatremia, rapid
management with ﬂuid restriction and, if necessary, admin-
istration of 30–50% oral urea solution, is necessary to avoid
persistent or increased hyponatremia, which carries the risk
of brain damage [9, 16].
Inaddition,hemizygousboyshavetoavoidmassivewater
intake, as shown by the results observed during water-load
testing. In these patients, caution is particularly important
when environmental factors may encourage sharp rises in
water intake (sports activities, during heat waves, in the
summertime, etc.). However, boys bearing the mutation are
mainly at risk of developing severe hyponatremia during
infancy when their water intake is mostly under parental
control. In heterozygous females, the advice will depend on
the results of the water-load test and will range from normal
to cautious water or ﬂuid intake.
6. Conclusion
The prevalence of this recently recognized disease is diﬃcult
to determine in children, and adults. Although NSIAD does
not seem to have an early neonatal expression, the diagnosis
should systematically be considered in infants, children and
adults presenting with hyponatremia associated with high
urine osmolality. In males, the diagnosis will be easily made
by sequencing the AVPR2. In siblings, a water-load test
can be helpful in studying and advising female carriers.
The treatment of symptomatic patients is based on ﬂuid
restriction and, if necessary, administration of an oral urea
solution.Otherwise,treatmentismainlypreventiveandaims
to avoid poorly adapted ﬂuid intake.
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